Oral Drug Delivery Videos

  1. Surveying Analytical Tools For Combination Product Testing 6/10/2025

    In this episode of The Combination Products Handbook: The Series, host Tom von Gunden discusses Chapter 11 on analytical testing with the book’s editor, Susan Neadle, and chapter coauthor Jennifer Riter. Susan and Jennifer discuss various analytical methods for testing compatibility, performance, stability, and safety when combining drugs or biologics with delivery devices and device constituent parts.

  2. Integrating Regulatory Strategies For Advanced Therapy Development 10/8/2025

    In this segment of the Drug Delivery Leader Live online event, Next-Gen Drug Delivery: Rethinking Routes For New Therapies, James Wabby, head of global regulatory affairs for emerging device technologies and combination products at AbbVie, discuses critical components of an integrated regulatory strategy for advanced therapy product development. 

  3. An Orally Delivered Alternative Approach To Obesity With Aphaia's Steffen-Sebastian Bolz 4/23/2026

    Offering an alternative to injectable peptides, Chief Scientific Officer Steffen-Sebastian Bolz from Aphaia Pharma describes for videocast host Tom von Gunden an obesity treatment that leverages the body’s natural mechanisms for processing food and engaging the brain’s intake-management functions. The approach loads glucose into orally consumed beads that travel to the lower intestine and trigger combinations of brain-signaling hormones, including GLP-1s.

  4. Understanding The Global Regulatory Landscape For Combination Products 8/14/2025

    In this videocast episode, host Tom von Gunden discusses Chapter 14 of The Combination Products Handbook (CRC Press) with the book’s editor Susan Neadle, along with chapter coauthors Stephanie Goebel, Cherry Malonzo Marty, and Viky Verna. The group provides overviews of the commonalities and variances in regulatory definitions and guidances for combination products across global jurisdictions and agencies. 

  5. Choosing A CDMO For Oral Solids, Nasal And Pulmonary Dosage Forms 1/21/2025

    Learn about UK-based Upperton Pharma Solutions and the many advantages of partnering with a CDMO, including their extensive expertise and capabilities across oral solids and specialized nasal and pulmonary formulations.

  6. Patient- And Planet-Centric Bioavailability And Sustained Delivery

    By reducing the size of drug particles, nanoforming offers new opportunities — from increased bioavailability to sustained drug delivery. Discover the potential benefits supported by case studies.

  7. Leveraging The Target Product Profile For Oral Delivery Formulation 6/12/2026

    In this segment of the Drug Delivery Leader Live online event, Advanced Oral Delivery: Maximizing Molecules, Targets, And Adherence, Chief Editor Tom von Gunden asks panelist Jing Ling about front-of-mind formulation drivers for lab scientists. Ling leads with the Target Product Profile (TPP), and panelist Eduardo Jule echoes its importance. 

  8. Solid Form Screening Of Active Pharmaceutical Ingredients

    Explore the role of solid form services in helping meet accelerated timelines of the drug development lifecycle along with examples of robust workflows for fast and thorough solid form screens.

  9. Developing Therapy Delivery Options For Autoimmune And Allergic Diseases At Revolo Biotherapeutics 4/22/2025

    In this episode of In Combination, host Tom von Gunden combines the perspectives of three executives at Revolo Biotherapeutics – CEO Woody Bryan, Chief Scientific Officer Roly Foulkes, and Chief Medical Officer Kari Brown – in a discussion about developing and delivering peptide-based alternatives to steroids for allergic and autoimmune diseases.

  10. The Future Of Oral Drug Delivery: Expert Takes 6/12/2026

    In this final segment of the Drug Delivery Leader Live online event, Advanced Oral Delivery: Maximizing Molecules, Targets, And Adherence, Chief Editor Tom von Gunden invites the panelists to highlight a key to further advancements. Eduardo Jule points to bioavailability enhancers, Firouz Asgarzadeh to overcoming GI tract challenges, and Jing Ling to large molecule delivery development.